|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Investment securities | ||||||||||||||||||||
| Equity investments | ||||||||||||||||||||
| Loans held for sale, at lower of amortized cost or fair value | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Net loans receivable | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Property, equipment, and right-of-use lease assets, net | ||||||||||||||||||||
| Loan collateral in process of foreclosure | ||||||||||||||||||||
| Income tax receivable | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Short-term debt | ||||||||||||||||||||
| Deferred tax liabilities, net | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Income tax payable | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||
| Preferred stock (1,000,000 shares of $0.01 par value stock authorized-none outstanding) | ||||||||||||||||||||
| Common stock (50,000,000 shares of $0.01 par value stock authorized - 30,102,353 shares at June 30, 2026 and 29,592,592 shares at December 31, 2025 issued) | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Treasury stock (7,060,708 shares at June 30, 2026 and 6,280,909 at December 31, 2025) | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Non-controlling interest in consolidated subsidiaries | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
| Number of shares outstanding | ||||||||||||||||||||
| Book value per share |
Loading...
